Article Text
Abstract
Objective Lysine-specific demethylase 1 (LSD1) is a kind of flavin adenine dinucleotide–dependent amine oxidase that regulates normal cellular differentiation, gene activation, tumorigenesis, and progression. This study aims to detect the expression level of LSD1 in endometrial cancer and to explore its role in the progression and prognosis of endometrioid endometrial adenocarcinoma (EEA).
Methods Immunohistochemistry was used to examine the expression of LSD1 in 206 EEA specimens, 50 benign endometrial lesion specimens, and 45 normal endometrium specimens. χ2 Analysis, Kaplan-Meier method, and multivariate Cox proportional hazard analysis were applied for the statistical analysis.
Results Compared with normal endometrium and benign endometrial lesion (both P < 0.001), LSD1 was overexpressed in EEA. LSD1 expression was correlated with histological grade, International Federation of Gynecology and Obstetrics (FIGO) stage, vascular/lymphatic invasion, depth of myometrial invasion, and lymph node metastasis. Results of the Kaplan-Meier analysis indicated that LSD1 expression was associated with overall survival (OS) and disease-free survival (DFS) of EEA. The negative expression LSD1 group had longer OS and DFS than did the positive expression group. The difference was significant (both P < 0.001, log-rank test). Multivariate Cox regression analysis revealed that the LSD1 expression status was an independent prognostic factor for both OS (P = 0.027) and DFS (P = 0.016) of patients with EEA.
Conclusions Overexpression of LSD1 may contribute to the progression of EEA and may thus serve as a new biomarker to predict the prognosis of EEA.
- Endometrioid endometrial adenocarcinoma
- Immunohistochemistry
- LSD1
- Prognosis
Statistics from Altmetric.com
Footnotes
Y.-D.L. and M.D. equally contributed to the article.
This work was supported by the Natural Science Foundation of Heilongjiang Province, China (grant H201336).
The authors declare no conflicts of interest.